PRAGUE, June 25, 2011 /PRNewswire/ --
The SHARP-study has shown that lowering LDL cholesterol with
ezetimibe/simvastatinleads to a significant reduction in major
atherosclerotic events among CKD-patients. Whether it also has a
favourable effect on renal disease progression was another of the